Jazz Pharmaceuticals plc (NASDAQ: JAZZ) Q4 2022 revenue was $972.12 million an 8% increase compared to 896.73 million in Q4 2021.
Financial Highlights
-
GAAP net loss for 2022 was $(224.1) million, or $(3.58) per diluted share, compared to $(329.7) million, or $(5.52) per diluted share, for 2021.
-
GAAP net loss for Q4 2022 was $(240.7) million, or $(3.82) per diluted share, compared to $(35.4) million, or $(0.57) per diluted share, for Q4 2021.
-
Net revenue for 2022 was $3.7 billion, an 18% increase compared to $3.1 billion in 2021.
-
As of December 31, 2022, cash and cash equivalents were $881.5 million, and the outstanding principal …